Roche deal gives new anti-HCV to China start-up
This article was originally published in Scrip
Roche is showing a great deal of faith in its partners in China: it has put the development of its Phase II protease inhibitor for hepatitis C, danoprevir, in the Chinese market in the hands of Ascletis, a two-year-old Hangzhou based start-up backed by a real estate billionaire. China is one of Roche's main growth markets – it recorded 20% sales growth there in the first quarter, with sales of some oncology products up nearly 40%.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.